InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
56,829.92
(
-2.52%
)
Post# of 252503
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

caravon

Send PM Follow Ignore
Followers 13
Posts 1058
Boards Moderated 0
Alias Born 02/21/2007

caravon

Re: DonShimoda post# 153109

Wednesday, 11/28/2012 10:10:16 AM

Wednesday, November 28, 2012 10:10:16 AM

Post# of 252503
Speaking about ARQL and NSCLC, according to Lazard's presentation, there are still 4 Tivantinib clinical trials are going including Marquee.

Consequently, at this moment, it is too early to discuss Roche's Metmab 1st-to-market NSCLC advantage. Roche's NSCLC trial will have just 480 pts and will take 4 years to complete. They could easily enroll and complete the trial in under 2 years but they are not rushing...
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up